Tumour-specific enhancement of thermoradiotherapy at mild temperatures by the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid

By Murata R.   Horsman M. R.  

International Journal of Hyperthermia, Vol. 20, Iss. 4, 2004-06 ,pp. : 393-404

Informa Healthcare

Access to resources Recommend Favorite

The antitumour agent 5,6-dimethylxanthenone-4-acetic acid acts in vitro on human mononuclear cells as a co-stimulator with other inducers of tumour necrosis factor

By Philpott M.   Ching L.-M.   Baguley B.C.  

European Journal of Cancer, Vol. 37, Iss. 15, 2001-10 ,pp. : 1930-1937

Elsevier

Access to resources Recommend Favorite

In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac

By Zhou Shufeng   Paxton James W.   Kestell Philip   Tingle Malcolm D.   Ching Lai-Ming  

Cancer Chemotherapy and Pharmacology, Vol. 47, Iss. 4, 2001-04 ,pp. : 319-326

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial

By Jameson M.   Baguley B.   Kestell P.   Zhao L.   Paxton J.   Thompson P.   Waller S.  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 5, 2007-04 ,pp. : 681-687

Springer Publishing Company

Access to resources Recommend Favorite

NF-kappa B activation in vivo in both host and tumour cells by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)

By Woon S.-T.   Zwain S.   Schooltink M.A.   Newth A.L.   Baguley B.C.   Ching L.-M.  

European Journal of Cancer, Vol. 39, Iss. 8, 2003-05 ,pp. : 1176-1183

Elsevier

Access to resources Recommend Favorite